Abstract:
Endoscopic ultrasonography (EUS) has greater spatial resolution than other diagnostic imaging modalities. In addition, if gallbladder lesions are found and gallbladder cancer is suspected, EUS is an indispensable modality, enabling detailed tests for invasion depth evaluation using the Doppler mode and ultrasound agents. Furthermore, for gallbladder lesions, EUS fine-needle aspiration (EUS-FNA) can be used to differentiate benign and malignant forms of conditions, such as xanthogranulomatous cholecystitis, and collect evidence before chemotherapy. EUS-FNA is also useful for highly precise and specific diagnoses. However, the prevention of bile leakage, an accidental symptom, is highly important. Advancements in next-generation sequencing (NGS) technologies facilitate the application of multiple parallel sequencing to EUS-FNA samples. Several biomarkers are expected to stratify treatment for gallbladder cancer; however, NGS can unveil potential predictive genomic biomarkers for the treatment response. It is believed that NGS may be feasible with samples obtained using EUS-FNA, further increasing the demand for EUS-FNA.
摘要:
内窥镜超声(EUS)比其他诊断成像方式具有更大的空间分辨率。此外,如果发现胆囊病变并怀疑胆囊癌,EUS是一种不可或缺的模态,使用多普勒模式和超声试剂进行详细的侵入深度评估测试。此外,胆囊病变,EUS细针穿刺(EUS-FNA)可用于区分良性和恶性疾病,如黄色肉芽肿性胆囊炎,在化疗前收集证据.EUS-FNA也可用于高度精确和特异性的诊断。然而,预防胆漏,一个意外的症状,是非常重要的。下一代测序(NGS)技术的进步促进了对EUS-FNA样品的多重平行测序的应用。几种生物标志物有望对胆囊癌的治疗进行分层;然而,NGS可以揭示治疗反应的潜在预测性基因组生物标志物。据认为,使用EUS-FNA获得的样品可能是可行的,进一步增加了对EUS-FNA的需求。